{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:44:49Z","timestamp":1782398689327,"version":"3.54.5"},"reference-count":72,"publisher":"Oceanside Publications Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The diagnosis and management of anaphylaxis in pediatric populations can be a particularly formidable challenge due to its variable definitions and atypical symptom presentation, which can often masquerade as other conditions. This complexity often leads to delays\n in early recognition and timely intervention. Most pediatric anaphylaxis guidelines emphasize the importance of identifying and avoiding triggers, ensuring accurate dosing and prompt administration of epinephrine to prevent severe complications. There is also growing scientific interest in\n strategies to intervene early in food allergy development to prevent allergies and protect infants and children from severe allergic reactions.  <jats:bold>Objective:<\/jats:bold> This report aimed to review key aspects of the pathophysiology, epidemiology, management, and prevention of anaphylaxis\n in the pediatric population. Also, approved treatment modalities and future research to treat and prevent anaphylactic reactions are discussed.  <jats:bold>Methods:<\/jats:bold> A review of the medical literature was conducted by using terms that included anaphylaxis, severe allergic reaction,\n pediatric, prevalence, desensitization, and immunotherapy.  <jats:bold>Results:<\/jats:bold> Food allergies remain the leading trigger of pediatric anaphylaxis, followed by Hymenoptera venom, whereas drug allergies are less common in children compared with adults. A review of the literature underscores\n the importance of recognizing early signs and symptoms of anaphylaxis, particularly in preverbal infants, of identifying and eliminating key triggers and of prompt epinephrine administration in the immediate management of pediatric anaphylaxis. Advances in oral immunotherapy and other treatments\n (e.g., biologics) provide new management options. Notably, anti\u2010immunoglobulin E therapy with omalizumab has shown substantial protection against reactions to accidental food exposure in children as young as 1 year old and with food allergy.  <jats:bold>Conclusion:<\/jats:bold> This report\n explores critical aspects of anaphylaxis that affect allergic diseases in infants and children. Gaining a deeper understanding of age-specific triggers and the diverse symptoms of anaphylaxis will significantly enhance diagnosis, treatment, and prevention strategies, ultimately improving the\n timeliness of interventions. Recent approvals of novel therapies for food allergies, along with promising developments for future treatment and prevention of anaphylaxis in pediatric populations, hold exciting potential for better management of these conditions.<\/jats:p>","DOI":"10.2500\/aap.2025.46.250005","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:32:27Z","timestamp":1747441947000},"page":"168-184","source":"Crossref","is-referenced-by-count":5,"title":["Anaphylaxis in children: Latest insights"],"prefix":"10.2500","volume":"46","author":[{"given":"Stefano","family":"Luccioli","sequence":"first","affiliation":[{"name":"From the Division of Rheumatology, Immunology and Allergy, Department of Medicine, Georgetown School of Medicine, Washington, D.C. and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Seabol","sequence":"additional","affiliation":[{"name":"Department of Medicine, Georgetown School of Medicine, Washington, D.C."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","first-page":"685","article-title":"Allergic diseases and asthma","volume-title":"Immunology IV: Clinical Applications in Health and Disease","author":"Luccioli","year":"2012"},{"key":"B2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0091-6749(02)70118-8","article-title":"Portier, Richet, and the discovery of anaphylaxis: a centennial","volume":"110","author":"Cohen","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"B3","first-page":"381","article-title":"Immunological studies of an atypical (myeloma) immunoglobulin","volume":"13","author":"Johansson","year":"1967","journal-title":"Immunology"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.4049\/jimmunol.99.6.1187","article-title":"Identification of gamma-E-antibodies as a carrier of reaginic activity","volume":"99","author":"Ishizaka","year":"1967","journal-title":"J Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"692","DOI":"10.4315\/0362-028X.JFP-16-443","article-title":"A limited survey of dark chocolate bars obtained in the United States for undeclared milk and peanut allergens","volume":"80","author":"Bedford","year":"2017","journal-title":"J Food Prot"},{"key":"B6","doi-asserted-by":"crossref","first-page":"100472","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World Allergy Organization Anaphylaxis Guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J"},{"key":"B7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2014Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network Symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/all.15032","article-title":"EAACI Guidelines: Anaphylaxis (2021 update)","volume":"77","author":"Muraro","year":"2022","journal-title":"Allergy"},{"key":"B9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: a 2023 practice parameter update","volume":"132","author":"Golden","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaci.2022.10.014","article-title":"An update on anaphylaxis and urticaria","volume":"150","author":"Worm","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2017.06.003","article-title":"The pathophysiology of anaphylaxis","volume":"140","author":"Reber","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.jaci.2009.12.981","article-title":"Anaphylaxis","volume":"125","author":"Simons","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.coi.2013.09.002","article-title":"Emerging antigens involved in allergic responses","volume":"25","author":"Platts-Mills","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.14309\/ajg.0000000000002268","article-title":"Clinical presentation of alpha-gal syndrome in pediatric gastroenterology and response to mammalian dietary elimination","volume":"118","author":"Busing","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"12413","DOI":"10.1073\/pnas.1105695108","article-title":"Identification of markers that distinguish IgE\u2014from IgG-mediated anaphylaxis","volume":"108","author":"Khodoun","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B16","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/all.12677","article-title":"Pathophysiological mechanisms of exercise-induced anaphylaxis: an EAACI position statement","volume":"70","author":"Ansley","year":"2015","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jaip.2014.03.007","article-title":"Mast cell activation disorders","volume":"2","author":"Akin","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","article-title":"Global classification of mast cell activation disorders: an ICD-10-CM\u2013adjusted proposal of the ECNM-AIM Consortium","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","article-title":"Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations","volume":"128","author":"Hamilton","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jaip.2019.10.048","article-title":"Idiopathic anaphylaxis: a form of mast cell activation syndrome","volume":"8","author":"Giannetti","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B21","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/ijms22052684","article-title":"Mediator-related symptoms and anaphylaxis in children with mastocytosis","volume":"22","author":"Brockow","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jaip.2019.08.022","article-title":"Mast cell activation syndrome: tools for diagnosis and differential diagnosis","volume":"8","author":"Weiler","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B23","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.jaip.2021.03.005","article-title":"The genetic basis and clinical impact of hereditary alpha-tryptasemia","volume":"9","author":"Luskin","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B24","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/all.13732","article-title":"The global incidence and prevalence of anaphylaxis in children in the general population: a systematic review","volume":"74","author":"Wang","year":"2019","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/all.12272","article-title":"The epidemiology of anaphylaxis in Europe: a systematic review","volume":"68","author":"Panesar","year":"2013","journal-title":"Allergy"},{"key":"B26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaip.2016.08.013","article-title":"Increasing emergency department visits for anaphylaxis, 2005-2014","volume":"5","author":"Motosue","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B27","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaip.2019.11.027","article-title":"Global trends in anaphylaxis epidemiology and clinical implications","volume":"8","author":"Turner","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B28","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaci.2014.10.021","article-title":"Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012","volume":"135","author":"Turner","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JAA.S123053","article-title":"Anaphylaxis across two Canadian pediatric centers: evaluating management disparities","volume":"10","author":"Lee","year":"2016","journal-title":"J Asthma Allergy"},{"key":"B30","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/pai.12908","article-title":"National trends in emergency department visits and hospitalizations for food-induced anaphylaxis in US children","volume":"29","author":"Motosue","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"key":"B31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/iid3.201","article-title":"Disparities in rate, triggers, and management in pediatric and adult cases of suspected drug-induced anaphylaxis in Canada","volume":"6","author":"Gabrielli","year":"2018","journal-title":"Immun Inflamm Dis"},{"key":"B32","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jaip.2023.01.029","article-title":"Trends and variation in pediatric anaphylaxis care from 2016 to 2022","volume":"11","author":"Dribin","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B33","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jaci.2015.11.015","article-title":"Anaphylaxis in children and adolescents: the European Anaphylaxis Registry","volume":"137","author":"Grabenhenrich","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"crossref","first-page":"n251","DOI":"10.1136\/bmj.n251","article-title":"Food anaphylaxis in the United Kingdom: analysis of national data, 1998-2018","volume":"372","author":"Baseggio Conrado","year":"2021","journal-title":"BMJ"},{"key":"B35","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1111\/all.13483","article-title":"French Group for Pediatric Intensive Care and Emergencies (GFRUP). Anaphylaxis admissions to pediatric intensive care units in France","volume":"73","author":"Pouessel","year":"2018","journal-title":"Allergy"},{"key":"B36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/cea.14528","article-title":"Trends in childhood anaphylaxis in Singapore: 2015\u20132022","volume":"54","author":"Goh","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"B37","doi-asserted-by":"crossref","first-page":"100449","DOI":"10.1016\/j.waojou.2020.100449","article-title":"A multicenter anaphylaxis registry in Korea: clinical characteristics and acute treatment details from infants to older adults","volume":"13","author":"Jeong","year":"2020","journal-title":"World Allergy Organ J"},{"key":"B38","first-page":"120","article-title":"Current situation of anaphylaxis in Japan: data from the Anaphylaxis Registry of Training and Teaching Facilities certified by the Japanese Society of Allergy","volume":"71","author":"Sato","year":"2022","journal-title":"Arerugi"},{"key":"B39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaci.2021.12.795","article-title":"Changes in Australian food anaphylaxis admission rates following introduction of updated allergy prevention guidelines","volume":"150","author":"Mullins","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2500\/jfa.2024.6.240002","article-title":"Anaphylaxis: definition and criteria","volume":"6","author":"Shaker","year":"2024","journal-title":"J Food Allergy"},{"key":"B41","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jaci.2020.08.015","article-title":"Persistent, refractory, and biphasic anaphylaxis: a multidisciplinary Delphi study","volume":"146","author":"Dribin","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.18773\/austprescr.2021.016","article-title":"Updated anaphylaxis guidelines: management in infants and children","volume":"44","author":"Frith","year":"2021","journal-title":"Aust Prescr"},{"key":"B43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jpeds.2010.10.017","article-title":"Age-related differences in the clinical presentation of food-induced anaphylaxis","volume":"158","author":"Rudders","year":"2011","journal-title":"J Pediatr"},{"key":"B44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaip.2020.09.018","article-title":"Food-induced anaphylaxis in infants: can new evidence assist with implementation of food allergy prevention and treatment?","volume":"9","author":"Tsuang","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B45","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jaip.2018.10.052","article-title":"Guiding principles for the recognition, diagnosis, and management of infants with anaphylaxis: an Expert Panel Consensus","volume":"7","author":"Greenhawt","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B46","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaci.2014.09.014","article-title":"Anaphylaxis: unique aspects of clinical diagnosis and management in infants (birth to age 2 years)","volume":"135","author":"Simons","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaip.2020.11.005","article-title":"Caregiver-reported presentation of severe food-induced allergic reactions in infants and toddlers","volume":"9","author":"Pistiner","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B48","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00431-017-3048-z","article-title":"Clinical features and treatment of pediatric patients with drug-induced anaphylaxis: a study based on pharmacovigilance data","volume":"177","author":"Xing","year":"2018","journal-title":"Eur J Pediatr"},{"key":"B49","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.anai.2021.06.019","article-title":"Inherited and acquired determinants of serum tryptase levels in humans","volume":"127","author":"Lyons","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaip.2022.09.006","article-title":"The evolution of our understanding of penicillin allergy: 1942-2022","volume":"11","author":"Macy","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B51","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis\u2014a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis","volume":"145","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B52","article-title":"FDA approves first nasal spray for treatment of anaphylaxis","year":"2024"},{"key":"B53","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.anai.2023.08.606","article-title":"Managing anaphylaxis: epinephrine, antihistamines, and corticosteroids: more than 10 years of Cross-Canada Anaphylaxis Registry data","volume":"131","author":"Delli Colli","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B54","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2017.05.022","article-title":"Do corticosteroids prevent biphasic anaphylaxis?","volume":"5","author":"Alqurashi","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B55","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.anai.2014.12.022","article-title":"Treatment of allergic reactions and quality of life among caregivers of food-allergic children","volume":"114","author":"Ward","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2500\/jfa.2023.5.230002","article-title":"Mechanisms of desensitization with oral immunotherapy and epicutaneous immunotherapy","volume":"5","author":"Bellanti","year":"2023","journal-title":"J Food Allergy"},{"key":"B57","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 oral immunotherapy for peanut allergy","volume":"379","author":"Vickery","year":"2018","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.jaip.2023.03.015","article-title":"Research advances in mast cell biology and their translation into novel therapies for anaphylaxis","volume":"11","author":"Dispenza","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","article-title":"Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: Results of two phase 3 randomised controlled trials","volume":"403","author":"Maurer","year":"2024","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"key":"B62","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2222.2007.02650.x","article-title":"Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection","volume":"37","author":"Cruz","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"B63","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.4049\/jimmunol.1601026","article-title":"Cutting edge: IgE plays an active role in tumor immunosurveillance in mice","volume":"197","author":"Nigro","year":"2016","journal-title":"J Immunol"},{"key":"B64","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B65","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.intimp.2010.12.018","article-title":"Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor","volume":"11","author":"MacGlashan","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"B66","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/all.13166","article-title":"BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils","volume":"72","author":"Smiljkovic","year":"2017","journal-title":"Allergy"},{"key":"B67","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1172\/JCI138448","article-title":"Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"J Clin Invest"},{"key":"B68","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jaci.2017.03.013","article-title":"Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity","volume":"140","author":"Regan","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B69","doi-asserted-by":"crossref","first-page":"e172335","DOI":"10.1172\/JCI172335","article-title":"A phase II study of Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis","volume":"133","author":"Suresh","year":"2023","journal-title":"J Clin Invest"},{"key":"B70","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/all.13262","article-title":"EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy","volume":"73","author":"Sturm","year":"2018","journal-title":"Allergy"},{"key":"B71","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1365-2222.2011.03788.x","article-title":"Diagnosis and management of Hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines","volume":"41","author":"Krishna","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"B72","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13223-017-0204-y","article-title":"Safety of 100 \u00b5g venom immunotherapy rush protocols in children compared to adults","volume":"13","author":"Stoevesandt","year":"2017","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000003\/art00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T04:33:11Z","timestamp":1761021191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5,1]]}},"alternative-id":["1088-5412(20250501)46:3L.168;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250005","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}